Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAPCAAMHO2: Heparin Dosing in Hybrid Surgery for Cerebral Aneurysm and AVM
NCT03306836Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2016
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of dextrose monohydrate + heparin sodium in cerebral aneurysm and Arteriovenous Malformation (AVM) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Activated coagulation time safety coverage rate at 48 hours. Status: unknown.
02
Drugs
dextrose monohydrate + heparin sodium
03
Conditions
cerebral aneurysmArteriovenous Malformation (AVM)
Beyond the preview
Go deeper on NCT03306836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306836.